SpringerLink
Log in

Post-treatment T1 shortening in primary CNS lymphoma

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The incidence of primary central nervous system lymphoma (PCNSL) has increased over the past two decades. The MR imaging appearance of PCNSL plays a central role in the initial diagnosis, management and follow-up of patients. The purpose of this study was to describe the presence and frequency of the pre-contrast T1 hyperintensity (T1h) that is sometimes identified in the region of enhancing neoplastic disease following treatment of PCNSL. We also explored possible causes for this phenomenon that, to the best of our knowledge, has not been previously described. The MR imaging and relevant medical records of 221 patients with pathologically confirmed PCNSL were retrospectively reviewed. Only patients with both treatment and follow-up imaging at our institution were eligible for inclusion in the study. Patients with evidence of post-procedural blood products (pre-contrast bright T1 lesions) prior to the initiation of therapy were excluded. Out of 221 patients, 119 met the eligibility criteria and were included in this investigation. Following treatment, 75 patients (63 %) developed pre-contrast T1h not attributable to blood products. All patients with this finding had been treated with methotrexate chemotherapy. The development of pre-contrast T1h following treatment for PCNSL is common. The hyperintense T1 signal in these patients may be caused by the biochemical response of tumor cells to treatment. To assess the prognostic significance of this novel finding, additional studies focusing on disease recurrence and patient survival are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

GRE:

Gradient recalled echo

FLAIR:

Fluid-attenuated inversion recovery

PCNSL:

Primary central nervous system lymphoma

SWI:

Susceptibility-weighted imaging

T1h:

T1 hyperintensity

References

  1. Olson JE, Janney CA, Rao RD et al (2002) The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95:1504–1510

    Article  PubMed  Google Scholar 

  2. Sierra del Rio M, Rousseau A, Soussain C, Ricard D, Hoang-Xuan K (2009) Primary CNS lymphoma in immunocompetent patients. Oncologist 14:526–539

    Article  PubMed  CAS  Google Scholar 

  3. Eby NL, Grufferman S, Flannelly CM, Schold SC Jr, Vogel FS, Burger PC (1988) Increasing incidence of primary brain lymphoma in the US. Cancer 62:2461–2465

    Article  PubMed  CAS  Google Scholar 

  4. Jack CR Jr, Reese DF, Scheithauer BW (1986) Radiographic findings in 32 cases of primary CNS lymphoma. AJR Am J Roentgenol 146:271–276

    PubMed  Google Scholar 

  5. Kuker W, Nagele T, Thiel E, Weller M, Herlinger U (2005) Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology 65:1129–1131

    Article  PubMed  CAS  Google Scholar 

  6. Haldorsen IS, Espeland A, Larsson EM (2011) Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 32:984–992

    Article  PubMed  CAS  Google Scholar 

  7. DeAngelis LM (1990) Primary central nervous system lymphoma imitates multiple sclerosis. J Neurooncol 1990(9):177–181

    Article  Google Scholar 

  8. Ayuso-Peralta L, Orti-Pareja M, Zurdo-Hernandez M et al (2001) Cerebral lymphoma presenting as a leukoencephalopathy. J Neurol Neurosurg Psychiatry 71:243–246

    Article  PubMed  CAS  Google Scholar 

  9. DeAngelis LM (1993) Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan. Ann Neurol 33:308–311

    Article  PubMed  CAS  Google Scholar 

  10. Johnson BA, Fram EK, Johnson PC, Jacobowitz R (1997) The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol 18:563–572

    PubMed  CAS  Google Scholar 

  11. Lai R, Rosenblum MK, DeAngelis LM (2002) Primary CNS lymphoma: a whole-brain disease? Neurology 59:1557–1562

    Article  PubMed  Google Scholar 

  12. Glass J, Gruber ML, Cher L, Hochberg FH (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81:188–195

    Article  PubMed  CAS  Google Scholar 

  13. Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16:859–863

    PubMed  CAS  Google Scholar 

  14. Ferreri AJ, Reni M, Villa E (2000) Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 11:927–937

    Article  PubMed  CAS  Google Scholar 

  15. Fliessbach K, Urbach H, Helmstaedter C et al (2003) Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60:563–568

    Article  PubMed  Google Scholar 

  16. Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND (2005) Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 26:258–265

    PubMed  Google Scholar 

  17. Cakirer S, Karaarsian E, Arslan A (2003) Spontaneously T1-hyperintense lesions of the brain on MRI: a pictorial review. Curr Probl Diagn Radiol 32:194–217

    Article  PubMed  Google Scholar 

  18. Bonneville F, Cattin F, Marsot-Dupuch K, Dormant D, Bonneville JF, Chiras J (2006) T1 signal hyperintensity in the sellar region: spectrum of findings. Radiographics 26:93–113

    Article  PubMed  Google Scholar 

  19. Rubenstein J, Fischbein N, Aldape K, Burton E, Shuman M (2002) Hemorrhage and VEGF expression in a case of primary CNS lymphoma. J Neurooncol 58:53–56

    Article  PubMed  Google Scholar 

  20. Kim IY, Jung S, Jung TY, Kang SS, Choi C (2008) Primary central nervous system lymphoma presenting as an acute massive intracerebral hemorrhage: case report with immunohistochemical study. Surg Neurol 70:308–311

    Article  PubMed  Google Scholar 

  21. Kimura N, Ishibashi M, Masuda T et al (2009) Primary central nervous system lymphoma with cortical laminar hemorrhage. J Neurol Sci 15(287):281–284

    Article  Google Scholar 

  22. Rogers LR (2003) Cerebrovascular complications in cancer patients. Neurol Clin 21:167–192

    Article  PubMed  Google Scholar 

  23. Wall RT, Harlan JM, Harker LA, Striker GE (1980) Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 18:113–121

    Article  PubMed  CAS  Google Scholar 

  24. Ling Q, Hajjar KA (2000) Inhibition of endothelial cell thromboresistance by homocysteine. J Nutr 130(suppl.):373–376

    Google Scholar 

  25. Haimes AB, Zimmerman RD, Morgello S et al (1989) MR imaging of brain abscesses. AJR Am J Roentgenol 152:1073–1085

    PubMed  CAS  Google Scholar 

  26. Baba A, Yamagami S, Mizuo H, Iwata H (1980) Microassay of cysteine sulfinic acid by an enzymatic cycling method. Anal Biochem 101:288–293

    Article  PubMed  CAS  Google Scholar 

  27. Pullan LM, Olney JW, Price MT et al (1987) Excitatory amino acid receptor potency and subclass specificity of sulfur-containing amino acids. J Neurochem 49:1301–1307

    Article  PubMed  CAS  Google Scholar 

  28. Curras MC, Dingledine R (1992) Selectivity of amino acid transmitters acting at N-methyl-D-aspartate and amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors. Mol Pharmacol 41:520–526

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None

Author information

Authors and Affiliations

  1. Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA

    Sasan Karimi, Vaios Hatzoglou, Vineet Punia & Sasan Partovi

  2. Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA

    Lauren E. Abrey & Lisa M. Deangelis

Authors
  1. Sasan Karimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vaios Hatzoglou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vineet Punia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sasan Partovi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lauren E. Abrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lisa M. Deangelis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sasan Karimi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karimi, S., Hatzoglou, V., Punia, V. et al. Post-treatment T1 shortening in primary CNS lymphoma. J Neurooncol 111, 25–31 (2013). https://doi.org/10.1007/s11060-012-0984-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-012-0984-3

Keywords

Search

Navigation